Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies
Cancer Medicine · 2024
DOI: 10.1002/cam4.70028 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Medicine, 2024. Verfasst von Courtney D DiNardo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Azacitidine, Proto-Oncogene Proteins c-mdm2, Antineoplastic Combined Chemotherapy Protocols, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Mouse double minute‐2 homolog (MDM2) plays a key role in downregulating p53 activity in hematologic malignancies, and its overexpression is associated with poor outcomes.
Methods
This phase 1 study assessed the safety and efficacy of different dosing regimens of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine (AZA) in patients with relapsed or refractory acute myeloid leukemia or high‐risk myelodysplastic syndromes.
Results
Seventy‐four patients (monotherapy, n = 57; milademetan‐AZA combination, n = 17) were treated. The maximum tolerated dose of milademetan was 160 mg once daily given for the first 14–21 days of 28‐day cycles as monotherapy and on Days 5–14 in combination with AZA. Dose‐limiting toxicities were gastrointestinal, fatigue, or renal/electrolyte abnormalities. Treatment‐emergent adverse events related to milademetan occurred in 82.5% and 64.7% of participants in the monotherapy and AZA combination arms, respectively. Two participants (4.2%) in the monotherapy arm achieved complete remission (CR), and 1 (2.1%) achieved CR with incomplete blood count recovery (CRi). Two participants (13.3%) achieved CRi in the combination arm. New TP53 mutations, detected only during milademetan monotherapy, were found pre‐existing below standard detection frequency by droplet digital polymerase chain reaction.
Interpretation
Milademetan was relatively well tolerated in this population; however, despite signals of activity, clinical efficacy was minimal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- University of California, San Francisco, California, USA.
- Roswell Park Comprehensive Care Center, Buffalo, New York, USA.
- University of Kansas Medical Center, Kansas City, Kansas, USA.
- Department of Pediatrics, City of Hope, Duarte, California, USA.
- Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA.
ORCID-Profile: Courtney D DiNardo
Zitieren
APA
DiNardo, C. D., Olin, R., Wang, E. S., Skikne, B., Rosenthal, J., Kumar, P., Sumi, H., Hizukuri, Y., Hong, Y., Patel, P., Seki, T., Duan, T., Lesegretain, A., & Andreeff, M. (2024). Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer Medicine. https://doi.org/10.1002/cam4.70028
Vancouver
DiNardo CD, Olin R, Wang ES, Skikne B, Rosenthal J, Kumar P, et al. Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer Medicine. 2024. doi:10.1002/cam4.70028
BibTeX
@article{DiNardo2024,
author = {DiNardo, Courtney D and Olin, Rebecca and Wang, Eunice S and Skikne, Barry and Rosenthal, Joseph and Kumar, Prasanna and Sumi, Hiroyuki and Hizukuri, Yoshiyuki and Hong, Ying and Patel, Parul and Seki, Takahiko and Duan, Tao and Lesegretain, Arnaud and Andreeff, Michael},
title = {Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70028}
}
EUVIMED